Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Hong Sik Lee"

Keywords

Publication year

"Hong Sik Lee"

Original Articles
Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test
Jong Jin Hyun, Yeon Seok Seo, Hyonggin An, Sun Young Yim, Min Ho Seo, Hye Sook Kim, Chang Ha Kim, Ji Hoon Kim, Bora Keum, Yong Sik Kim, Hyung Joon Yim, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Korean J Hepatol 2012;18(1):56-62.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.56
Background/Aims

The nonspecific clinical presentation of acute hepatitis A (AHA) mandates the detection of anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in the serum for obtaining a definitive diagnosis. However, IgM anti-HAV might not be present during the early phase of the disease. The aim of this study was to determine the optimal time for repeating the IgM anti-HAV test (HAV test) in AHA patients with a negative initial test.

Methods

In total, 261 patients hospitalized with AHA were enrolled for this retrospective study. AHA was diagnosed when the test for IgM anti-HAV was positive and the serum alanine aminotransferase (ALT) level was ≥400 IU/L. Repeat HAV test was conducted after 1-2 weeks if the initial HAV test was negative but AHA was still clinically suspected.

Results

The results of the initial HAV test were negative in 28 (10.7%) patients. The intervals from symptom onset to the initial-HAV-test day and from the peak-ALT day to the initial-HAV-test day were significantly shorter in the negative-initial-HAV-test group, but on multivariate analysis only the latter was significantly associated with negative results for the initial HAV test (β=-0.978; odds ratio [95% confidence interval]=0.376 [0.189-0.747]; P=0.005). The HAV test was positive in all patients when it was performed at least 2 days after the peak-ALT day.

Conclusions

The results of HAV tests were significantly associated with the interval from the peak-ALT day to the HAV-test day. The optimal time for repeating the HAV test in clinically suspicious AHA patients with a negative initial HAV test appears to be at least 2 days after the peak-ALT day.

Citations

Citations to this article as recorded by  Crossref logo
  • Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens
    Robert A. Kozak, Candace Rutherford, Melissa Richard-Greenblatt, N. Y. Elizabeth Chau, Ana Cabrera, Mia Biondi, Jamie Borlang, Jaqueline Day, Carla Osiowy, Sumathi Ramachandran, Nancy Mayer, Laurel Glaser, Marek Smieja
    Viruses.2022; 14(1): 159.     CrossRef
  • Assay Sensitivity Difference Can Induce Anti-Hepatitis A Virus IgM Non-Reactive But Total (IgM and IgG) Reactive Results in Early Acute Hepatitis A
    Soo-Kyung Kim, Kwon Yoo, Jungwon Huh
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • False positive anti-hepatitis A virus immunoglobulin M in autoimmune hepatitis/primary biliary cholangitis overlap syndrome: A case report
    Jun Yan, Yan-Sha He, Yi Song, Xin-Yu Chen, Hua-Bao Liu, Chun-Yan Rao
    World Journal of Clinical Cases.2021; 9(22): 6464.     CrossRef
  • Case of severe acute hepatitis A virus infection in United Nations peacekeepers in South Sudan
    Chen Li, H Su, J Hu, H Duan, J Ji
    Journal of the Royal Army Medical Corps.2019; 165(3): 198.     CrossRef
  • The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited
    Robério Amorim de Almeida Pondé
    Archives of Virology.2017; 162(12): 3587.     CrossRef
  • Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review
    Kuan-Yin Lin, Guan-Jhou Chen, Yu-Lin Lee, Yi-Chia Huang, Aristine Cheng, Hsin-Yun Sun, Sui-Yuan Chang, Chun-Eng Liu, Chien-Ching Hung
    World Journal of Gastroenterology.2017; 23(20): 3589.     CrossRef
  • Window period of anti-hepatitis A virus immunoglobulin M antibodies in diagnosing acute hepatitis A
    Hyo Keun Lee, Kyung-Ah Kim, June Sung Lee, Nam-Hoon Kim, Won Ki Bae, Tae June Song
    European Journal of Gastroenterology & Hepatology.2013; 25(6): 665.     CrossRef
  • Two cases of acute liver failure caused by hepatitis A which were negative for serum IgM-HA antibody at the early stage of the onset
    Masaru Muraoka, Masayuki Kurosaki, Shuya Matsuda, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shouko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Nobuyuki Enomoto
    Kanzo.2013; 54(8): 553.     CrossRef
  • Multiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A
    Nae-Yun Heo, Young-Suk Lim, Jihyun An, Sun-Young Ko, Heung-Bum Oh
    Clinical and Molecular Hepatology.2012; 18(4): 397.     CrossRef
  • 10,401 View
  • 61 Download
  • Crossref
Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels
Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Korean J Hepatol 2011;17(2):130-138.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.130
Background/Aims

Several studies suggested that serum cystatin C (CysC) is more useful than serum creatinine (Cr) for the assessment of renal function in patients with liver cirrhosis. This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and normal Cr level.

Methods

We enrolled patients with cirrhotic ascites and a normal serum Cr level (<1.2 mg/dL). GFR was measured by 99mTc-DTPA renal scan. Serum Cr, CysC, and Cr clearance (CCr) were measured on the same day. Significant renal impairment and severe renal impairment were defined as GFR <60 mL/min and GFR <30 mL/min, respectively.

Results

Eighty-nine patients with cirrhotic ascites were enrolled in the study (63 men and 26 women; age, 55±11 years). Forty-seven (52.8%) and 42 (47.2%) patients were in Child-Pugh grade B and C, respectively. Serum Cr and CysC levels and GFR were 0.8±0.2 mg/dL, 1.1±0.3 mg/L, and 73.4±25.5 mL/min, respectively. Significant and severe renal impairment were noted in 28 (31.5%) and 2 (2.2%) patients, respectively. GFR was well correlated with serum Cr, CysC, and e-GFRMDRD, while it was not correlated with e-GFRC&G. In multivariate analysis, only CysC was significantly correlated with GFR (β, 45.620; 95% CI, 23.042-68.198; P<0.001). Serum CysC level was the only independent predictor for significant renal impairment.

Conclusions

Significant renal dysfunction was not rare in patients with cirrhotic ascites, even their serum Cr level is normal. Serum CysC is a useful marker for detecting significant renal dysfunction in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Diagnostic value of serum TGF-β1 and CysC in type 2 diabetic kidney disease: a cross-sectional study
    Yi Kang, Qian Jin, Mengqi Zhou, Huijuan Zheng, Xiaobin Li, Aoshuang Li, Jing Wei Zhou, Jie Lv, Yaoxian Wang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Zonula occludens 1 as a novel biomarker in decompensated alcoholic cirrhosis with hepatorenal syndrome
    Balasubramaniyan Vairappan, Raj Kumar, Mukta Wyawahare
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Improved outcomes of kidney after liver transplantation after the implementation of the safety net policy
    Rose Mary Attieh, Ramez M. Ibrahim, Peter Ghali, Andrew Keaveny, Kristopher Croome, David Hodge, Launia White, Hani M. Wadei
    Liver Transplantation.2024; 30(6): 582.     CrossRef
  • The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury
    Ahmed M. Abd El Wahab, Abeer Awadeen, Mostafa M. Mansour, Rasha Shemies
    Therapeutic Apheresis and Dialysis.2023; 27(3): 419.     CrossRef
  • Role of Novel Kidney Biomarkers in Patients With Cirrhosis and After Liver Transplantation
    Sumeet K. Asrani, Nagasri Shankar, Briget da Graca, Mitra K. Nadim, Andres Cardenas
    Liver Transplantation.2022; 28(3): 466.     CrossRef
  • Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
    Fathia Elsayed Asal, Mohamed Yousef, Hend Atteya Abdelkhalek Abdraboh, Sherief Abd-Elsalam, Ahmed Abdelaziz Abdelaziz Shama, Mohamed Elbahnasawy, Mohammed H Elnaggar, Hesham Ahmed Alsrogy, Heba Elashry
    The Open Biomarkers Journal.2022;[Epub]     CrossRef
  • Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis
    Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani
    Liver Transplantation.2021; 27(11): 1538.     CrossRef
  • Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure
    Praveen Jha, Ashish Kumar Jha, Vishwa Mohan Dayal, Sanjeev Kumar Jha, Amarendra Kumar
    Indian Journal of Gastroenterology.2021; 40(6): 563.     CrossRef
  • Serum cystatin C unmasks renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate
    Balaraman Velayudham, RemiGeorge Thomas, C Vasudevan, RP Senthilkumar, Thirumalvalavan, Murugesan
    Saudi Journal of Kidney Diseases and Transplantation.2020; 31(6): 1320.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients
    Dong Wang, Jia-Fu Feng, An-Qun Wang, Yu-Wei Yang, Yun-Shuang Liu
    Medicine.2017; 96(20): e6949.     CrossRef
  • How to evaluate renal function in stable cirrhotic patients
    Florencia I. Aiello, Magdalena Bajo, Fernanda Marti, Carlos G. Musso
    Postgraduate Medicine.2017; 129(8): 866.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis
    Mahmoud Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat Assem, Gasser El-Azab
    International Journal of Hepatology.2015; 2015: 1.     CrossRef
  • GFR Estimating Equations and Liver Disease
    Tomasz Beben, Dena E. Rifkin
    Advances in Chronic Kidney Disease.2015; 22(5): 337.     CrossRef
  • Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine
    Bilyana Teneva, Emiliya Karaslavova
    Open Medicine.2014; 9(5): 625.     CrossRef
  • Update on Cystatin C: Incorporation Into Clinical Practice
    Michael G. Shlipak, Monica D. Mattes, Carmen A. Peralta
    American Journal of Kidney Diseases.2013; 62(3): 595.     CrossRef
  • Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation
    Jeffrey C Sirota, Angela Walcher, Sarah Faubel, Alkesh Jani, Kim McFann, Prasad Devarajan, Connie L Davis, Charles L Edelstein
    BMC Nephrology.2013;[Epub]     CrossRef
  • Impact of creatinine production on the agreement between glomerular filtration rate estimates using cystatin C-derived, and 4- and 6-variable Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equ
    Esperanza F. Hermida-Cadahia, Natalia Lampon, J. Carlos Tutor
    Upsala Journal of Medical Sciences.2012; 117(4): 402.     CrossRef
  • Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury
    W. Stephen Waring, Alasdair Moonie
    Clinical Toxicology.2011; 49(8): 720.     CrossRef
  • 12,545 View
  • 89 Download
  • Crossref